| Literature DB >> 29243485 |
Anne Marie Boustani1, Darko Pucar1, Lawrence Saperstein1.
Abstract
Prostate cancer is a common malignancy with various treatments from surveillance, surgery, radiation and chemotherapy. The institution of appropriate, effective treatment relies in part on accurate imaging. Molecular imaging techniques offer an opportunity for increased timely detection of prostate cancer, its recurrence, as well as metastatic disease. Advancements within the field of molecular imaging have been complex with some agents targeting receptors and others acting as metabolic intermediaries. In this article, we provide an overview of the most clinically relevant radiotracers to date based on a combination of the five states model and the National Comprehensive Cancer Network Guidelines.Entities:
Mesh:
Year: 2018 PMID: 29243485 PMCID: PMC5966010 DOI: 10.1259/bjr.20170736
Source DB: PubMed Journal: Br J Radiol ISSN: 0007-1285 Impact factor: 3.039